The Kratom Council

Latest / Science

Science

A Product Sold As Kava Sent A Patient Into Opioid Withdrawal. The Label Said Akuamma, And The Lab Found Kratom.

Seven empty unlabelled clear glass sample vials standing in a brushed steel rack on a grey laboratory bench.

In June, the Journal of Addiction Medicine published a case report describing a patient who developed severe opioid-like withdrawal after heavy use of a gas station beverage sold as kava. The report is short, it concerns one person, and it is the most concrete documentation this publication has seen of a pattern the trade has been describing anecdotally for months.

What the treating clinicians found is worth setting out carefully, because each step of it is a fact about labelling rather than a claim about any plant.

What The Case Report Describes

The patient was a 36-year-old man with opioid use disorder in sustained remission. After heavy use of a commercially available shot marketed as kava, he developed rapid tolerance, frequent redosing, nocturnal withdrawal, and prominent gastrointestinal and autonomic symptoms. The authors record that his symptoms did not respond to benzodiazepines and improved rapidly with buprenorphine and naloxone, which they take to suggest dependence mediated at the mu-opioid receptor. They also note that the presentation was inconsistent with withdrawal from kava itself, which they describe as typically mild and anxiety predominant.

Two findings about the product follow. The authors state that review of the product labelling indicated the presence of akuamma, the seed of the West African tree Picralima nitida. Separately, qualitative testing of independently purchased samples of the same product by the University of Alabama at Birmingham toxicology laboratory confirmed the presence of kratom derivatives and kavalactones.

The authors place this in a specific policy context. They note it occurred against kratom prohibition in Alabama, and they point to overlapping manufacturer product lines. Their conclusion is about mislabelled or adulterated polyherbal products, and about clinicians needing to consider opioid-mediated mechanisms when evaluating withdrawal from supplements sold as non-opioid.

This is a single case report. It establishes what was found in one product purchased in one state, and the authors present it as a clinical caution rather than a survey of the market. This publication reports it as that and does not extend it into a general claim about any category of product.

Why Akuamma Is On The Label At All

Akuamma is being offered in the trade as a replacement for 7-hydroxymitragynine. This publication has reviewed wholesale marketing material pitching it in exactly those terms.

The reason it is available to pitch is regulatory rather than chemical. Akuammine and the other akuamma alkaloids are not scheduled federally. They are not reached by the Drug Enforcement Administration's August 26 order, which named mitragynine pseudoindoxyl, MGM-15 and MGM-16. They are not reached by the pending 7-OH threshold order, which is written against Mitragyna speciosa material and 7-OH content. They are not reached by state Kratom Consumer Protection Acts, which regulate kratom. Picralima nitida is a different plant in a different family, so a law written about kratom does not describe it.

That is the whole of the advantage. It is not a statement about what akuamma does.

What The Published Pharmacology Actually Says

The research literature on the akuamma alkaloids is small, old in parts, and less favourable to the marketing than the marketing suggests.

Work published in the European Journal of Pharmacology in 1998 by Menzies and colleagues at Glasgow Caledonian University assayed five alkaloids from Picralima nitida seeds. Akuammidine showed a preference for mu-opioid binding sites. Akuammicine showed highest affinity at kappa sites. Akuammine, the most abundant of them, showed its highest affinity at mu sites but behaved as an antagonist there rather than an agonist. The authors concluded that these alkaloids possess varying degrees of agonist and antagonist activity at opioid receptors while possessing neither high affinity nor selectivity for any of them.

A 2020 paper in the Journal of Natural Products by Creed and colleagues, working across the University of Illinois Chicago and Purdue, isolated six akuamma alkaloids in high purity and screened them against more than 40 central nervous system receptors. The opioid receptors were their primary targets. Three showed micromolar activity at the mu receptor. When those were tested for analgesic properties, the authors report they demonstrated limited efficacy in assays of thermal nociception, and they state plainly that their findings contradict previous reports of the antinociceptive properties of these alkaloids and the traditional use of akuamma seeds as analgesics.

A 2023 paper in the Journal of Medicinal Chemistry from overlapping authors describes akuammine and pseudoakuammigine as weak agonists of the mu receptor that produce minimal effects in animal models of antinociception.

Read together, the published work does not describe a potent opioid. It describes a set of weakly active natural alkaloids whose reputation the researchers themselves have questioned in print.

The Part That Matters For What Comes Next

The same laboratories that established how weak the natural alkaloids are have also published how to make them considerably stronger.

The 2023 Journal of Medicinal Chemistry paper prepared 22 semisynthetic derivatives of akuammine and pseudoakuammigine in order to probe the opioid receptors. The authors report that introducing a phenethyl group at one position on akuammine produced a seventy-fold increase in potency at the mu receptor and a seven-fold increase in selectivity for it, and that the resulting compound showed increased efficacy in animal assays of antinociception. A 2024 paper from the same group reports semisynthetic derivatives of akuammicine with more than a two-hundred-fold improvement in potency at the kappa receptor and nearly complete selectivity for it.

A 2025 review in Natural Product Reports places this work in its proper frame. It surveys semisynthesis of opioid-targeting natural products and treats mitragynine, akuammine, akuammicine and salvinorin A as members of the same research programme: isolated natural products modified to yield ligands with improved affinity and potency.

That framing is the point for anyone tracking this market. Mitragynine is on that list. The path from mitragynine to the compounds the DEA scheduled in August ran through exactly this kind of chemistry, published in exactly this kind of journal, years before the products appeared on shelves. This publication traced that sequence in its history of the loophole molecule.

The equivalent chemistry for the akuamma alkaloids is now in the literature, and the starting material is a plant no American drug law describes.

What This Report Does Not Establish

Nothing here says that akuamma products on sale today contain semisynthetic derivatives. This publication has seen no laboratory result, no enforcement action and no regulatory filing indicating that, and does not assert it. What the record shows is a published route and an unregulated starting material, which is a description of opportunity rather than of conduct.

Nothing here characterises what akuamma does to a person. The pharmacology described above belongs to the cited researchers and is reported as their findings in controlled assays, most of them in animals or isolated tissue. None of it is this publication's assessment, and none of it should be read as safety information in either direction.

The case report concerns one patient and one product. The laboratory confirmation of kratom derivatives in that product is the authors' finding about samples they purchased, not a general statement about products sold as kava.

The Kratom Council does not run advocacy campaigns and takes no position here on whether prohibition of kratom leaf drives substitution. That argument is being made by others, on the record, and is worth reporting as theirs when they make it.

Sources

  1. Malhotra A, McPherson GE, Scott KS, Li L — "When Kava Isn't Kava: Opioid-like Withdrawal Responsive to Buprenorphine: A Case Study," Journal of Addiction Medicine (June 29, 2026)
  2. Menzies JR, Paterson SJ, Duwiejua M, Corbett AD — "Opioid activity of alkaloids extracted from Picralima nitida," European Journal of Pharmacology 350(1):101-8 (1998)
  3. Creed SM, Gutridge AM, Argade MD, Hennessy MR, Friesen JB, Pauli GF, van Rijn RM, Riley AP — "Isolation and Pharmacological Characterization of Six Opioidergic Alkaloids," Journal of Natural Products 84(1):71-80 (2020)
  4. Hennessy MR et al. — "Modified Akuamma Alkaloids with Increased Potency at the Mu-opioid Receptor," Journal of Medicinal Chemistry 66(5):3312-3326 (2023)
  5. Hennessy MR et al. — "Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine," Journal of Medicinal Chemistry 67(23):20842-20857 (2024)
  6. Riley AP — "Semi-synthesis in the exploration of opioid-targeting natural products," Natural Product Reports 42(10):1664-1675 (2025)
  7. Lewin G, Le Menez P, Rolland Y, Renouard A, Giesen-Crouse E — "Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors," Journal of Natural Products 55(3):380-4 (1992)
  8. Federal Register — DEA notice of intent, 7-hydroxymitragynine above a specified threshold, Docket No. DEA-1570 (July 6, 2026)
  9. Federal Register — temporary scheduling order, mitragynine pseudoindoxyl, MGM-15 and MGM-16, Docket No. DEA-1644 (effective August 26, 2026)

← Back to all coverage

Get new reporting by email